Richard C. Mohs, Ph.D. is the Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation, an organization devoted to enhancing the speed and quality of drug development for Alzheimer’s disease. He retired in 2015 from Eli Lilly and Company where he held several leadership positions including Vice President for Neuroscience Early Clinical Development (2012-2015) and Leader of the Global Alzheimer’s Drug Development Team (2007-2012). Dr. Mohs received the Ph.D. is psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford Medical School. Before joining Eli Lilly in 2002, Dr. Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. He is the author or co-author of over 350 scientific papers, including those describing clinical trials that led to the approval, in the U.S. and other countries, of cholinergic drug treatments for Alzheimer’s disease. In addition to his work for the GAP Foundation, Dr. Mohs serves as a consultant to academic institutions and biopharmaceutical companies including Agenebio, a Baltimore-based company developing an SV2A antagonist for treatment of mild cognitive impairment. He also serves as a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation and is a member of the Board of Directors of the Greater Indiana Chapter of the Alzheimer’s Association.